united therapeutics glp-1 receptor agonist products Frontiers Revolutionizing obesity treatment: The emerging

GoodRx reports that while satisfaction with GLP-1s for weight loss is high, costs and access issues significantly impact patient experiences.

Discover if there are generic GLP-1 drugs available and how they can impact diabetes management and weight loss.

See if you qualify for compensation and how to file.

A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year

Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile

A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks